Table 3

Group 2. baseline demographics of participants having two assessments prior to and two assessments subsequent to starting antidopaminergic medication and matched controls, showing the mean with SD in brackets

Control group (those not taking dopamine medication but assessed at the same time points)
(n=104)		Pre-antidopaminergic and post-antidopaminergic treatment group
(n=90)
Number of visits4.4 (0.6)
4–6		4.3 (0.5)
4–6
Gender (m:f)52:4841:49
ISCED3.8 (1.2)
1–6		3.5 (1.2)
2–6
Age52.6 (12)
28–83		53 (11.3)
26–79
CAG repeat length42.9 (4.9)
38–52		43.4 (2.6)
39–51
DBS388 (78.2)
167.5–589		392.9 (66.1)
202.5–567
TFC score
Max score 13		10.1 (3.2)
0–13		9.2 (3.2)
0–13
Time since diagnosis
(years)		4.1 (4.2)
0–20		4 (4)
0–20
Motor score (UHDRS)
Max score 124		28.1 (18.18)
5–95		31.3 (15.4)
7–80
Total chorea score (UHDRS)
Max score 28		7.8 (4.9)
0–21		9.5* (5)
0–21
Irritability
(PBA)
Max score 32		1.8 (2.8)
0–13		4.3† (5.6)
0–24
Depression
(PBA)
Max score 48		2.7 (3.9)
0–18		4.2* (5.5)
0–23
Apathy
(PBA)
Max score 16		2 (3.7)
0–16		2.8 (4.1)
0–16
MMSE
Max score 30		27.5 (2.6)
17–30		26.3 (2.9)
16–30
Composite cognitive z-score1.5 (5.4)
−11.2 to 15.8		1.7† (4.8)
19.2–11.3

  • ISCED, The International Standard Classification of Education; CAG, cytosine-adenine-guanine; MMSE, Mini-Mental State Examination.

  • *Indicates a significant difference (p<0.005) when compared with the control non-antidopaminergic medication group.

  • †Indicates a significant difference (p<0.001) when compared with the control non-antidopaminergic medication group.

  • DBS, disease burden score; PBA, problems behavioural assessment; TFC, total functional capacity; UHDRS, Unified Huntington Disease Rating Scale.